Contact Us
The company’s solution serves self-insured employers, health plans and secondary payers.
emergingtherapies.comCrawled Oct 14, 2026
The company’s solution serves self-insured employers, health plans and secondary payers.
ETS focuses solely on CGT and transplant.
The policy describes the personal information the company may collect and how it may be used.
Emerging Therapy Solutions monitors the **PDUFA date** for a Huntington’s disease therapy to aid payer planning. The milestone marks a critical step in the therapy’s regulatory review process, influencing coverage and reimbursement strategies for healthcare providers.
The FDA approves **Voceryq**, a novel cell and gene therapy, expanding treatment options for rare genetic disorders. Emerging Therapy Solutions highlights the approval as a pivotal advancement in precision medicine, though patient eligibility and long-term efficacy remain under review. The therapy targets a specific genetic mutation, offering hope for previously untreatable conditions.
Emerging Therapy Solutions participates in the **Academy of Managed Care Pharmacy Nexus 2026** conference. The company engages with industry stakeholders to discuss advancements in therapy solutions for managed care pharmacy. The event highlights collaboration opportunities in healthcare innovation and patient care strategies.
Emerging Therapy Solutions appears at **#39** on the *Minneapolis/St. Paul Business Journal* **2026 Fast 50** list, recognizing the Twin Cities’ fastest-growing private companies. The ranking highlights its rapid expansion among local businesses. The list is compiled annually by the *Business Journal* to showcase high-growth enterprises in the region.
Emerging Therapy Solutions participates in the 2026 Cell & Gene Therapy Symposium. The company engages with industry leaders to explore advancements in gene therapy technologies and collaborative opportunities. The event highlights cutting-edge research and potential partnerships in the field.